Barry Callebaut has halted manufacturing operations at its Weize chocolate plant in Belgium as a precautionary measure while conducting its root cause analysis and risk assessment after detecting salmonella in a production lot.
The company identified lecithin as the source of the contamination.
All chocolate products manufactured at the facility since June 25 have been placed on hold.
After the analysis, the lines will be cleaned and sanitized before production can resume.
Barry Callebaut, which informed the Belgian food authorities (FAVV) about the incident, said that their robust food safety programs allowed them to identify lecithin as the source of the contamination quickly.
The company added that they are reaching out to all customers who may have received impacted products.
The news comes after Ferrero temporarily suspended production at its Arlon facility in Belgium after the site was linked to a salmonella outbreak.


US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge
Trump Says Iran Ceasefire Near Collapse as Oil Prices Surge
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases
Trump-Iran Tensions Keep Oil Prices Elevated Amid Hormuz Supply Fears
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks
US Inflation Expected to Rise Again in April as Fed Signals Higher Interest Rates
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors
US Auto Industry Urges Trump to Block Chinese EV Market Access
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 



